Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Hepatology ; 48(6): 1769-78, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19026009

RESUMO

UNLABELLED: Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-naïve individual, raising concerns about possible full drug resistance. To investigate the prevalence of dominant resistance mutations against specifically targeted antiviral therapy for HCV (STAT-C) in the population, we analyzed HCV genome sequences from 507 treatment-naïve patients infected with HCV genotype 1 from the United States, Germany, and Switzerland. Phylogenetic sequence analysis and viral load data were used to identify the possible spread of replication-competent, drug-resistant viral strains in the population and to infer the consequences of these mutations upon viral replication in vivo. Mutations described to confer resistance to the protease inhibitors Telaprevir, BILN2061, ITMN-191, SCH6 and Boceprevir; the NS5B polymerase inhibitor AG-021541; and to the NS4A antagonist ACH-806 were observed mostly as sporadic, unrelated cases, at frequencies between 0.3% and 2.8% in the population, including two patients with possible multidrug resistance. Collectively, however, 8.6% of the patients infected with genotype 1a and 1.4% of those infected with genotype 1b carried at least one dominant resistance mutation. Viral loads were high in the majority of these patients, suggesting that drug-resistant viral strains might achieve replication levels comparable to nonresistant viruses in vivo. CONCLUSION: Naturally occurring dominant STAT-C resistance mutations are common in treatment-naïve patients infected with HCV genotype 1. Their influence on treatment outcome should further be characterized to evaluate possible benefits of drug resistance testing for individual tailoring of drug combinations when treatment options are limited due to previous nonresponse to peginterferon and ribavirin.


Assuntos
Antivirais/uso terapêutico , Farmacorresistência Viral/genética , Hepacivirus/enzimologia , Hepatite C/tratamento farmacológico , Mutação/genética , Inibidores de Proteases/uso terapêutico , Antivirais/farmacologia , Carbamatos/farmacologia , Carbamatos/uso terapêutico , Estudos de Coortes , Feminino , Testes Genéticos , Hepacivirus/genética , Hepacivirus/patogenicidade , Hepatite C/sangue , Hepatite C/virologia , Humanos , Compostos Macrocíclicos/farmacologia , Compostos Macrocíclicos/uso terapêutico , Masculino , Oligopeptídeos/farmacologia , Oligopeptídeos/uso terapêutico , Feniltioureia/análogos & derivados , Feniltioureia/farmacologia , Feniltioureia/uso terapêutico , Filogenia , Prolina/análogos & derivados , Prolina/farmacologia , Prolina/uso terapêutico , Quinolinas/farmacologia , Quinolinas/uso terapêutico , Tiazóis/farmacologia , Tiazóis/uso terapêutico , Carga Viral , Proteínas não Estruturais Virais/antagonistas & inibidores
3.
Dig Dis Sci ; 52(10): 2540-9, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17410445

RESUMO

In a prospective therapeutic trial, features of the hepatitis C quasispecies were investigated as possible markers of therapeutic response. Individuals chronically infected with hepatitis C genotype 1 received antiviral therapy consisting of alpha-interferon plus ribavirin. The study targeted the most rapidly evolving segment of the viral genome, hypervariable region 1 within the envelope-2 gene. Among individuals failing to clear virus in response to therapy, significant differences were observed between quasispecies of African-American and Caucasian subjects. While distance measures for synonymous substitutions were similar between racial subgroups, measures of distance at the amino acid level (nonsynonymous substitutions) varied significantly. Taken together, the observed patterns of variability corresponded to reduced host selection pressure against hypervariable region 1 in African-American nonresponders. Reduced selection pressure was present at baseline and persisted through treatment and follow-up, suggesting population stratification of host factors that influence selection pressure on hepatitis C virus.


Assuntos
Negro ou Afro-Americano , Hepacivirus/genética , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/uso terapêutico , Polietilenoglicóis/uso terapêutico , Ribavirina/uso terapêutico , Seleção Genética , Proteínas Virais/genética , Adulto , Antivirais/uso terapêutico , Portadores de Fármacos , Feminino , Seguimentos , Genótipo , Hepatite C Crônica/sangue , Hepatite C Crônica/etnologia , Humanos , Interferon alfa-2 , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Estudos Prospectivos , RNA Viral/genética , Proteínas Recombinantes , Tennessee/epidemiologia , Falha de Tratamento , Proteínas Virais/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...